Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Sponsor
University Health Network, Toronto
Study ID
NCT03702309
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.

Key Dates

First listed
Oct 11, 2018
Start date
Aug 3, 2017
Status verified
Nov 2025
Primary completion
Jul 6, 2026
Completion
Jul 6, 2026

Study Design

Enrollment
2,500 participants (estimated)

Arms

  • Arm: LIBERATE
    Patients with either histological confirmation of a solid tumor or hematological malignancy, or patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).

Primary Outcome Measure

Collection and annotation of biospecimens [ Time Frame: Through study completion, up to 5 years ]

Central Contacts

Find similar trials

Related Studies